RADIOPHARMACEUTICALS FOR THERAPY

1. Introduction: Radiopharmaceuticals Play an Important Role in Both Diagnostic and Therapeutic Nuclear Medicine
2. Therapeutic Radionuclides Decay with Particle Emission for Therapeutic Applications
3. Alpha Radionuclide Therapy
4. Auger Electron-Based Radionuclide Therapy
5. Reactor-Produced Therapeutic Radionuclides
6. Accelerator-Produced Therapeutic Radionuclides
7. Radionuclide Generator Systems Represent Convenient Production Systems to Provide Therapeutic Radionuclides
8. Availability of Alpha-Emitting Radioisotopes by Reactor and Accelerator Production and via Decay of Naturally Occurring Parents
9. Radioimmunotherapy (RIT)
10. Peptide Receptor Radionuclide Therapy (PRRT)
11. Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Hepatic Cancer
12. Therapeutic Radiopharmaceuticals for Bone Pain Palliation
13. Locoregional Radionuclide Therapy for Nonmelanoma Skin Cancer (NMSC)
14. Radionuclide Synovectomy: Treatment of Inflammation of the Synovial Joints
15. Inhibition of Arterial Restenosis Following Balloon Angioplasty
16. Moving Forward: Expected Opportunities for the Development of New Therapeutic Agents Based on Nanotechnologies
17. Translation of Radiopharmaceuticals from Bench to Bedside: Regulatory and Manufacturing Issues

This book provides detailed information on therapeutic radiopharmaceuticals and discusses emerging technologies which have potential for broad clinical implementation. Recent advances in molecular biology, radiopharmaceutical chemistry and radioisotope production have stimulated a new era for the use of radiopharmaceuticals for targeted radionuclide therapy (TRT). Emerging clinical trials include use of peptides and monoclonal antibodies radiolabeled with therapeutic radionuclides for cancer therapy. In addition, small molecules are used for the treatment of chronic diseases such as metastatic bone pain palliation and radiation synovectomy of inflammatory joints. In the interventional arena, therapy of primary and metastatic liver cancer and arterial restenosis following angioplasty of both the coronary and peripheral arteries are being explored. Reactor and accelerator production of therapeutic radioisotopes is also integrated into these discussions. The development and use of radiopharmaceutical targeting characteristics required for treatment of specific disease processes and how these are implemented for radiopharmaceutical design strategies are also described. Radiopharmaceuticals for Therapy will benefit audiences in nuclear medicine and radionuclide therapy and will thus prove an invaluable source of up-to-date information for students, radiopharmaceutical scientists and professionals working in the radiopharmacy and nuclear medicine specialties.

Features
• First comprehensive discussion of the basic science integrated with descriptions of their clinical applications
• Provides overview of radioisotope production and processing technologies, key targeting strategies for treatment of cancer and chronic disease processes, and how radiopharmaceuticals are developed, tested and evaluated in clinical trials
• Combines all aspects of the availability of radioisotopes and their use for radiopharmaceutical development and applications in clinical nuclear medicine

Authors
• F. F. (Russ) Knapp, Jr., Ph.D. Emeritus Program Manager Corporate Fellow ORNL Medical Radioisotope Program Nuclear Security and Isotope Division Bldg. 4501, MS 6229 Oak Ridge National Laboratory (ORNL) PO Box 2008 1 Bethel Valley Road Oak Ridge, TN 37830-6229
• Dr. Ashutosh Dash Head, Isotope Production and Applications Division Professor, Homi Bhabha National Institute Bhabha Atomic Research Centre Mumbai, 400085, India